Privia Health Group, Inc. (NASDAQ:PRVA) Shares Bought by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. grew its position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 300,000 shares of the company's stock after acquiring an additional 50,000 shares during the period. Alyeska Investment Group L.P. owned about 0.25% of Privia Health Group worth $5,865,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. First Horizon Advisors Inc. raised its holdings in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after purchasing an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Privia Health Group by 7,833.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock worth $47,000 after buying an additional 2,350 shares during the last quarter. Financial Management Professionals Inc. acquired a new stake in Privia Health Group in the 4th quarter valued at about $51,000. Quadrant Capital Group LLC increased its holdings in Privia Health Group by 11.8% during the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock valued at $95,000 after acquiring an additional 511 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Privia Health Group by 185.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock worth $98,000 after acquiring an additional 3,249 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PRVA. Truist Financial raised their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. Canaccord Genuity Group boosted their price target on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Barclays increased their price objective on Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Thursday, April 10th. Piper Sandler upped their price objective on shares of Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $29.00 target price on shares of Privia Health Group in a research note on Monday, April 28th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $27.38.

Privia Health Group Trading Down 0.2 %

PRVA traded down $0.05 during trading on Friday, hitting $25.02. 1,314,984 shares of the company's stock were exchanged, compared to its average volume of 766,349. The stock has a 50 day moving average price of $23.38 and a 200 day moving average price of $22.31. Privia Health Group, Inc. has a 1 year low of $15.92 and a 1 year high of $26.09. The firm has a market cap of $3.04 billion, a P/E ratio of 250.23, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87.

Insider Buying and Selling

In other news, CFO David Mountcastle sold 3,445 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $80,371.85. Following the completion of the transaction, the chief financial officer now directly owns 176,231 shares in the company, valued at approximately $4,111,469.23. This represents a 1.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Matthew Shawn Morris sold 10,309 shares of Privia Health Group stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $240,508.97. Following the sale, the director now directly owns 59,792 shares in the company, valued at $1,394,947.36. This trade represents a 14.71 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 34,484 shares of company stock valued at $799,163. Company insiders own 10.70% of the company's stock.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.